How do I choose an ELN or LIMS for my biotech lab?
Choose an ELN or LIMS by first deciding which records it will hold and whether any are GxP. Research-only use needs strong access control, search, instrument integration and full data export. GxP use adds Part 11 requirements: secure audit trails, unique electronic signatures, role-based access and validation of your configured workflows. Score vendors on data integrity, identity integration, exit terms and total cost, not features alone.
ELN, LIMS or both
An electronic lab notebook records experiments: design, observations, results and the scientist's reasoning. A laboratory information management system manages samples, tests, results and workflows across a lab. Discovery teams usually start with an ELN; a LIMS becomes important once sample volume, QC testing or regulated release work grows. Some platforms do both, which is convenient but makes the GxP boundary harder to draw.
Define intended use and GxP scope first
Part 11 applies when the system holds records required by FDA predicate rules. FDA's 2018 data integrity guidance says each CGMP workflow on a computer system is an intended use that must be validated, with effort commensurate with risk, and that qualifying a platform does not show that your specific workflow runs correctly.
So write down which workflows will be regulated before you shortlist vendors. That list drives configuration, validation scope and cost.
Requirements to put in the RFP
- Single sign-on with your company identity, MFA and unique named accounts.
- Secure, time-stamped audit trails that cannot be disabled by users and can be reviewed and exported.
- Electronic signatures showing name, date, time and meaning, linked to the record.
- Role-based permissions separating authors, reviewers and administrators.
- Complete export of records and metadata in human-readable and electronic form.
- Instrument integration that preserves original dynamic data files.
- Backup, retention and vendor release-notification commitments, plus the vendor's validation package.
Contract and exit terms
Your data will outlive the contract. Confirm in writing that you own it, how a full export works including audit trails, how long data is kept after termination, and how upgrades are announced so you can assess them before they reach validated workflows. For device companies, FDA's CSA guidance lets you leverage supplier and cloud provider assurance, which makes a strong vendor package worth paying for.
Rolling it out
Implement in stages. Configure the platform for one team and its core workflows, connect it to company sign-on, and migrate only the legacy data you need, verifying it after transfer. For regulated workflows, complete risk-based validation and SOPs before go-live and train users on them. Then expand to other teams, reviewing permissions and audit trail settings at each step so the controls hold as usage grows.
Common follow-up questions
Is a vendor's "Part 11 compliant" claim enough?
No. Part 11 obligations fall on the company using the system. A vendor can supply compliant features, but compliance depends on your configuration, procedures, training and validation for your intended use.
Can we keep printouts instead of original instrument files?
Sometimes. FDA says a printout can serve as the original for simple instruments like balances, but dynamic records, such as FT-IR spectral files, cannot be replaced by a printout. Plan integrations that keep the original files.
Should a seed-stage biotech buy a LIMS?
Usually not yet. Most early teams need a governed ELN and good file management. Revisit a LIMS as sample volume, QC testing or GMP work approaches, and choose an ELN whose data you can export cleanly if you switch later.
LAN Service Group provides GxP-regulated IT for life-science companies, helping define ELN and LIMS requirements, integrate them with company identity and infrastructure, and support the IT side of validation.
Talk to LAN Service Group (888) 281-7243